Antibody-drug  ||| S:0 E:14 ||| JJ
conjugate  ||| S:14 E:24 ||| JJ
technology  ||| S:24 E:35 ||| NN
development  ||| S:35 E:47 ||| NN
for  ||| S:47 E:51 ||| IN
hematologic  ||| S:51 E:63 ||| JJ
disorders  ||| S:63 E:73 ||| NNS
Antibody-drug  ||| S:73 E:87 ||| JJ
conjugates  ||| S:87 E:98 ||| NNS
( ||| S:98 E:99 ||| -LRB-
ADCs ||| S:99 E:103 ||| NNP
)  ||| S:103 E:105 ||| -RRB-
combine  ||| S:105 E:113 ||| VB
cytotoxic  ||| S:113 E:123 ||| JJ
chemotherapy  ||| S:123 E:136 ||| NN
and  ||| S:136 E:140 ||| CC
antibody  ||| S:140 E:149 ||| NN
specificity ||| S:149 E:160 ||| NN
.  ||| S:160 E:162 ||| .
There  ||| S:162 E:168 ||| EX
are  ||| S:168 E:172 ||| VBP
4  ||| S:172 E:174 ||| CD
components  ||| S:174 E:185 ||| NNS
of  ||| S:185 E:188 ||| IN
ADC  ||| S:188 E:192 ||| NNP
technology ||| S:192 E:202 ||| NN
:  ||| S:202 E:204 ||| :
the  ||| S:204 E:208 ||| DT
cancer ||| S:208 E:214 ||| NN
,  ||| S:214 E:216 ||| ,
or  ||| S:216 E:219 ||| CC
target ||| S:219 E:225 ||| NN
,  ||| S:225 E:227 ||| ,
antigen ||| S:227 E:234 ||| NN
;  ||| S:234 E:236 ||| :
the  ||| S:236 E:240 ||| DT
antibody  ||| S:240 E:249 ||| NN
to  ||| S:249 E:252 ||| TO
that  ||| S:252 E:257 ||| DT
target ||| S:257 E:263 ||| NN
;  ||| S:263 E:265 ||| :
the  ||| S:265 E:269 ||| DT
linker  ||| S:269 E:276 ||| NN
that  ||| S:276 E:281 ||| WDT
connects  ||| S:281 E:290 ||| VBZ
the  ||| S:290 E:294 ||| DT
drug  ||| S:294 E:299 ||| NN
to  ||| S:299 E:302 ||| TO
the  ||| S:302 E:306 ||| DT
antibody ||| S:306 E:314 ||| NN
;  ||| S:314 E:316 ||| :
and  ||| S:316 E:320 ||| CC
the  ||| S:320 E:324 ||| DT
drug  ||| S:324 E:329 ||| NN
itself ||| S:329 E:335 ||| PRP
.  ||| S:335 E:337 ||| .
The  ||| S:337 E:341 ||| DT
antibody  ||| S:341 E:350 ||| NN
directs  ||| S:350 E:358 ||| VBZ
the  ||| S:358 E:362 ||| DT
cytotoxic  ||| S:362 E:372 ||| JJ
agent  ||| S:372 E:378 ||| NN
to  ||| S:378 E:381 ||| TO
the  ||| S:381 E:385 ||| DT
tumor  ||| S:385 E:391 ||| NN
cell ||| S:391 E:395 ||| NN
,  ||| S:395 E:397 ||| ,
thereby  ||| S:397 E:405 ||| RB
diminishing  ||| S:405 E:417 ||| VBG
the  ||| S:417 E:421 ||| DT
side  ||| S:421 E:426 ||| NN
effect  ||| S:426 E:433 ||| NN
profile  ||| S:433 E:441 ||| NN
of  ||| S:441 E:444 ||| IN
the  ||| S:444 E:448 ||| DT
cytotoxic  ||| S:448 E:458 ||| JJ
agent  ||| S:458 E:464 ||| NN
and  ||| S:464 E:468 ||| CC
enabling  ||| S:468 E:477 ||| VBG
delivery  ||| S:477 E:486 ||| NN
of  ||| S:486 E:489 ||| IN
a  ||| S:489 E:491 ||| DT
more  ||| S:491 E:496 ||| RBR
potent  ||| S:496 E:503 ||| JJ
therapeutic  ||| S:503 E:515 ||| NN
because  ||| S:515 E:523 ||| IN
of  ||| S:523 E:526 ||| IN
the  ||| S:526 E:530 ||| DT
ability  ||| S:530 E:538 ||| NN
to  ||| S:538 E:541 ||| TO
control  ||| S:541 E:549 ||| VB
the  ||| S:549 E:553 ||| DT
target  ||| S:553 E:560 ||| NN
and  ||| S:560 E:564 ||| CC
the  ||| S:564 E:568 ||| DT
side  ||| S:568 E:573 ||| NN
effects ||| S:573 E:580 ||| NNS
.  ||| S:580 E:582 ||| .
ADC  ||| S:582 E:586 ||| NNP
technology  ||| S:586 E:597 ||| NN
has  ||| S:597 E:601 ||| VBZ
vastly  ||| S:601 E:608 ||| RB
improved  ||| S:608 E:617 ||| VBN
within  ||| S:617 E:624 ||| IN
the  ||| S:624 E:628 ||| DT
last  ||| S:628 E:633 ||| JJ
several  ||| S:633 E:641 ||| JJ
years ||| S:641 E:646 ||| NNS
.  ||| S:646 E:648 ||| .
In  ||| S:648 E:651 ||| IN
early  ||| S:651 E:657 ||| JJ
ADCs ||| S:657 E:661 ||| NN
,  ||| S:661 E:663 ||| ,
the  ||| S:663 E:667 ||| DT
linkers  ||| S:667 E:675 ||| NN
were  ||| S:675 E:680 ||| VBD
too  ||| S:680 E:684 ||| RB
labile ||| S:684 E:690 ||| JJ
,  ||| S:690 E:692 ||| ,
which  ||| S:692 E:698 ||| WDT
led  ||| S:698 E:702 ||| VBD
to  ||| S:702 E:705 ||| TO
the  ||| S:705 E:709 ||| DT
release  ||| S:709 E:717 ||| NN
of  ||| S:717 E:720 ||| IN
free  ||| S:720 E:725 ||| JJ
drug  ||| S:725 E:730 ||| NN
in  ||| S:730 E:733 ||| IN
the  ||| S:733 E:737 ||| DT
circulation  ||| S:737 E:749 ||| NN
and  ||| S:749 E:753 ||| CC
consequent  ||| S:753 E:764 ||| JJ
off-target  ||| S:764 E:775 ||| JJ
toxicity ||| S:775 E:783 ||| NN
.  ||| S:783 E:785 ||| .
In  ||| S:785 E:788 ||| IN
the  ||| S:788 E:792 ||| DT
current  ||| S:792 E:800 ||| JJ
generation  ||| S:800 E:811 ||| NN
of  ||| S:811 E:814 ||| IN
ADCs ||| S:814 E:818 ||| NNP
,  ||| S:818 E:820 ||| ,
the  ||| S:820 E:824 ||| DT
linkers  ||| S:824 E:832 ||| NNS
are  ||| S:832 E:836 ||| VBP
more  ||| S:836 E:841 ||| RBR
stable ||| S:841 E:847 ||| JJ
,  ||| S:847 E:849 ||| ,
and  ||| S:849 E:853 ||| CC
the  ||| S:853 E:857 ||| DT
cytotoxic  ||| S:857 E:867 ||| JJ
agents  ||| S:867 E:874 ||| NNS
are  ||| S:874 E:878 ||| VBP
significantly  ||| S:878 E:892 ||| RB
more  ||| S:892 E:897 ||| RBR
potent ||| S:897 E:903 ||| JJ
.  ||| S:903 E:905 ||| .
ADCs  ||| S:905 E:910 ||| NNS
have  ||| S:910 E:915 ||| VBP
been  ||| S:915 E:920 ||| VBN
developed  ||| S:920 E:930 ||| VBN
against  ||| S:930 E:938 ||| IN
a  ||| S:938 E:940 ||| DT
variety  ||| S:940 E:948 ||| NN
of  ||| S:948 E:951 ||| IN
antigens  ||| S:951 E:960 ||| NN
and  ||| S:960 E:964 ||| CC
receptors ||| S:964 E:973 ||| NNS
,  ||| S:973 E:975 ||| ,
including  ||| S:975 E:985 ||| VBG
CD19 ||| S:985 E:989 ||| NNP
,  ||| S:989 E:991 ||| ,
CD22 ||| S:991 E:995 ||| NNP
,  ||| S:995 E:997 ||| ,
and  ||| S:997 E:1001 ||| CC
CD30 ||| S:1001 E:1005 ||| NNP
,  ||| S:1005 E:1007 ||| ,
and  ||| S:1007 E:1011 ||| CC
have  ||| S:1011 E:1016 ||| VBP
been  ||| S:1016 E:1021 ||| VBN
linked  ||| S:1021 E:1028 ||| VBN
to  ||| S:1028 E:1031 ||| TO
multiple  ||| S:1031 E:1040 ||| JJ
different  ||| S:1040 E:1050 ||| JJ
cytotoxic  ||| S:1050 E:1060 ||| JJ
agents ||| S:1060 E:1066 ||| NNS
,  ||| S:1066 E:1068 ||| ,
including  ||| S:1068 E:1078 ||| VBG
calicheamicin  ||| S:1078 E:1092 ||| NNS
and  ||| S:1092 E:1096 ||| CC
maytansinoid  ||| S:1096 E:1109 ||| JJ
derivatives ||| S:1109 E:1120 ||| NNS
.  ||| S:1120 E:1122 ||| .
The  ||| S:1122 E:1126 ||| DT
ADC  ||| S:1126 E:1130 ||| NNP
brentuximab  ||| S:1130 E:1142 ||| NN
vedotin  ||| S:1142 E:1150 ||| NNS
was  ||| S:1150 E:1154 ||| VBD
recently  ||| S:1154 E:1163 ||| RB
approved  ||| S:1163 E:1172 ||| VBN
by  ||| S:1172 E:1175 ||| IN
the  ||| S:1175 E:1179 ||| DT
US  ||| S:1179 E:1182 ||| NNP
Food  ||| S:1182 E:1187 ||| NNP
and  ||| S:1187 E:1191 ||| CC
Drug  ||| S:1191 E:1196 ||| NNP
Administration  ||| S:1196 E:1211 ||| NNP
for  ||| S:1211 E:1215 ||| IN
the  ||| S:1215 E:1219 ||| DT
treatment  ||| S:1219 E:1229 ||| NN
of  ||| S:1229 E:1232 ||| IN
patients  ||| S:1232 E:1241 ||| NNS
with  ||| S:1241 E:1246 ||| IN
Hodgkin  ||| S:1246 E:1254 ||| NNP
lymphoma  ||| S:1254 E:1263 ||| NN
after  ||| S:1263 E:1269 ||| IN
failure  ||| S:1269 E:1277 ||| NN
of  ||| S:1277 E:1280 ||| IN
autologous  ||| S:1280 E:1291 ||| JJ
stem  ||| S:1291 E:1296 ||| NN
cell  ||| S:1296 E:1301 ||| NN
transplant  ||| S:1301 E:1312 ||| NN
or  ||| S:1312 E:1315 ||| CC
at  ||| S:1315 E:1318 ||| IN
least  ||| S:1318 E:1324 ||| JJS
2  ||| S:1324 E:1326 ||| CD
prior  ||| S:1326 E:1332 ||| JJ
multiagent  ||| S:1332 E:1343 ||| JJ
chemotherapy  ||| S:1343 E:1356 ||| JJ
regimens ||| S:1356 E:1364 ||| NN
,  ||| S:1364 E:1366 ||| ,
and  ||| S:1366 E:1370 ||| CC
the  ||| S:1370 E:1374 ||| DT
treatment  ||| S:1374 E:1384 ||| NN
of  ||| S:1384 E:1387 ||| IN
patients  ||| S:1387 E:1396 ||| NNS
with  ||| S:1396 E:1401 ||| IN
systemic  ||| S:1401 E:1410 ||| JJ
anaplastic  ||| S:1410 E:1421 ||| JJ
large  ||| S:1421 E:1427 ||| JJ
cell  ||| S:1427 E:1432 ||| NN
lymphoma  ||| S:1432 E:1441 ||| NN
after  ||| S:1441 E:1447 ||| IN
failure  ||| S:1447 E:1455 ||| NN
of  ||| S:1455 E:1458 ||| IN
at  ||| S:1458 E:1461 ||| IN
least  ||| S:1461 E:1467 ||| JJS
1  ||| S:1467 E:1469 ||| CD
prior  ||| S:1469 E:1475 ||| JJ
multiagent  ||| S:1475 E:1486 ||| JJ
chemotherapy  ||| S:1486 E:1499 ||| JJ
regimen ||| S:1499 E:1506 ||| NN
.  ||| S:1506 E:1508 ||| .
Other  ||| S:1508 E:1514 ||| JJ
ADCs  ||| S:1514 E:1519 ||| NN
in  ||| S:1519 E:1522 ||| IN
clinical  ||| S:1522 E:1531 ||| JJ
trials  ||| S:1531 E:1538 ||| NNS
for  ||| S:1538 E:1542 ||| IN
hematologic  ||| S:1542 E:1554 ||| JJ
disorders  ||| S:1554 E:1564 ||| NNS
include  ||| S:1564 E:1572 ||| VBP
inotuzumab  ||| S:1572 E:1583 ||| JJ
ozogamicin ||| S:1583 E:1593 ||| NN
,  ||| S:1593 E:1595 ||| ,
SAR3419 ||| S:1595 E:1602 ||| NNP
,  ||| S:1602 E:1604 ||| ,
and  ||| S:1604 E:1608 ||| CC
gemtuzumab  ||| S:1608 E:1619 ||| JJ
ozogamicin ||| S:1619 E:1629 ||| NN
.  ||| S:1629 E:1631 ||| .
